| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 87,309 | - | 64,995 | 51,632 |
| Cost of goods sold | 41,289 | - | 31,538 | 17,286 |
| Research and development | 14,131 | - | 12,557 | 10,397 |
| Selling, general and administrative | 41,848 | - | 42,996 | 39,975 |
| Total operating expenses | 97,268 | - | 87,091 | 67,658 |
| (loss) income from operations | -9,959 | 7,095 | -22,096 | -16,026 |
| Interest expense | 22,051 | 20,486 | 19,431 | 15,082 |
| Loss on extinguishment of debt | 0 | 0 | - | - |
| Other income, net | 677 | 666 | 1,072 | 1,584 |
| Net loss | -31,333 | -12,725 | -40,455 | -29,524 |
| Comprehensive loss | -31,333 | -12,725 | -40,455 | -29,524 |
| Net loss per common share - basic (in dollars per share) | -0.16 | -0.06 | -0.21 | -0.15 |
| Net loss per common share - diluted (in dollars per share) | -0.16 | -0.06 | -0.21 | -0.15 |
| Weighted-average shares outstanding - basic (in shares) | 200,736,136 | 197,546,239 | 196,127,948 | 194,930,830 |
| Weighted-average shares outstanding - diluted (in shares) | 200,736,136 | 197,546,239 | 196,127,948 | 194,930,830 |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)